Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 May;31(5):609-618.
doi: 10.1016/j.annonc.2020.02.006. Epub 2020 Feb 20.

ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer

D Planchard  1 , N Reinmuth  2 , S Orlov  3 , J R Fischer  4 , S Sugawara  5 , S Mandziuk  6 , D Marquez-Medina  7 , S Novello  8 , Y Takeda  9 , R Soo  10 , K Park  11 , M McCleod  12 , S L Geater  13 , M Powell  14 , R May  14 , U Scheuring  15 , P Stockman  15 , D Kowalski  16
Affiliations
Free article
Clinical Trial

ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer

D Planchard et al. Ann Oncol. 2020 May.
Free article

Abstract

Background: Many patients with metastatic non-small-cell lung cancer (mNSCLC) experience disease progression after first- and second-line treatment; more treatment options are required for these patients. ARCTIC, a phase III, randomized, open-label study, assessed durvalumab ± tremelimumab versus standard of care (SoC) as ≥ third-line treatment of mNSCLC.

Patients and methods: ARCTIC comprised two independent sub-studies. Study A: 126 patients with ≥25% of tumor cells (TCs) expressing programmed cell death ligand-1 (PD-L1) were randomized (1 : 1) to durvalumab [up to 12 months 10 mg/kg every 2 weeks (q2w)] or SoC. Study B: 469 patients with PD-L1 TC <25% were randomized (3 : 2 : 2 : 1) to durvalumab + tremelimumab (12 weeks durvalumab 20 mg/kg + tremelimumab 1 mg/kg q4w then 34 weeks durvalumab 10 mg/kg q2w), SoC, durvalumab (up to 12 months 10 mg/kg q2w), or tremelimumab (24 weeks 10 mg/kg q4w then 24 weeks q12w). Primary end points: overall survival (OS) and progression-free survival (PFS) for durvalumab versus SoC (study A; descriptive only) and durvalumab + tremelimumab versus SoC (study B).

Results: Study A: median OS 11.7 (durvalumab) versus 6.8 (SoC) months {hazard ratio (HR) 0.63 [95% confidence interval (CI), 0.42-0.93]}; median PFS 3.8 (durvalumab) versus 2.2 (SoC) months [HR 0.71 (95% CI, 0.49-1.04)]. Study B: median OS 11.5 (durvalumab + tremelimumab) versus 8.7 (SoC) months [HR 0.80 (95% CI, 0.61-1.05); P = 0.109]. Median PFS of 3.5 months for both groups [HR 0.77 (95% CI, 0.59-1.01); P = 0.056]. Treatment-related grade 3/4 adverse events: 9.7% (durvalumab) and 44.4% (SoC; study A) and 22.0% (durvalumab + tremelimumab) and 36.4% (SoC; study B).

Conclusions: In heavily pretreated patients with mNSCLC, durvalumab demonstrated clinically meaningful improvements in OS and PFS versus SoC (patients with PD-L1 TC ≥25%); numerical improvements in OS and PFS for durvalumab + tremelimumab versus SoC were observed (patients with PD-L1 TC <25%). Safety profiles were consistent with previous studies.

Trial registration: Clinicaltrials.gov identifier: NCT02352948.

Keywords: ARCTIC; durvalumab; immunotherapy; metastatic non-small-cell lung cancer; tremelimumab.

PubMed Disclaimer

Conflict of interest statement

Disclosure DP has served in an advisory role and provided consultancy or lectures for AstraZeneca, Bristol-Myers Squibb, Boehringer-Ingelheim, Celgene, Daiichi Sankyo, Eli Lilly, Merck, Novartis, Pfizer, prIME Oncology, Peer CME, and Roche, has received honoraria from AstraZeneca, Bristol-Myers Squibb, Boehringer-Ingelheim, Celgene, Eli Lilly, Merck, Novartis, Pfizer, prIME Oncology, Peer CME, and Roche, has undertaken clinical trials research for AstraZeneca, Bristol-Myers Squibb, Boehringer-Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Roche, MedImmune, Sanofi-Aventis, Taiho Pharma, Novocure, and Daiichi Sankyo, and has received travel/accommodation/expenses from AstraZeneca, Roche, Novartis, prIME Oncology, and Pfizer. NR reports personal fees and non-financial support from AstraZeneca, Boehringer-Ingelheim, Hoffmann La-Roche, Bristol-Myers Squibb, and Pfizer, personal fees from MSD Sharp & Dohme and Takeda, and non-financial support from AbbVie, all outside the submitted work. SS has received lecture fees and research grants from AstraZeneca. DM-M has served as a speaker and advisory board member for Roche, Bristol-Myers Squibb, Boehringer-Ingelheim, MSD, and Pierre-Fabre. SN reports speakers’ bureau/advisory work for Eli Lilly, Roche, Bristol-Myers Squibb, Takeda, Boehringer-Ingelheim, AstraZeneca, MSD, Pfizer, Bayer, and AbbVie. YT has received research funding from Taiho, Boehringer-Ingelheim, Chugai, and Kyowa Hakko Kirin. RS has served as an advisory board member for AstraZeneca, Bristol-Myers Squibb, Boehringer-Ingelheim, Lilly, Merck, Novartis, Pfizer, Roche, Taiho, Takeda, and Yuhan, and has received research grants from AstraZeneca and Boehringer-Ingelheim. SLG has received non-financial support from Boehringer-Ingelheim, AstraZeneca, Sanofi-Aventis, and Novartis, and research grants from Boehringer-Ingelheim, AstraZeneca, and Novartis. RM, US, and PS are full-time employees of AstraZeneca. MP was a contractor for AstraZeneca at the time of the study. All remaining authors have declared no conflicts of interest.

Publication types

MeSH terms

Associated data